Investing.com - Sonnet Biotherapeutics Holdings (NASDAQ: SONN) reported first quarter EPS of $-0.3400, $0.16 better than the analyst estimate of $-0.4950. Revenue for the quarter came in at $36.45K versus the consensus estimate of $0.00.
Sonnet Biotherapeutics Holdings's stock price closed at $0.2300. It is down -76.1900% in the last 3 months and down -93.6900% in the last 12 months.
Sonnet Biotherapeutics Holdings saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Sonnet Biotherapeutics Holdings's stock price’s past reactions to earnings here.
According to InvestingPro, Sonnet Biotherapeutics Holdings's Financial Health score is "weak performance".
Check out Sonnet Biotherapeutics Holdings's recent earnings performance, and Sonnet Biotherapeutics Holdings's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar